tetano
Editor, Senior Moderator
Arthritis Res Ther. 2011 Dec 16;13(6):R209. [Epub ahead of print]
Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-TNF.
Kobie JJ, Zheng B, Bryk P, Barnes M, Ritchlin CT, Tabechian DA, Anandarajah AP, Looney RJ, Thiele RG, Anolik JH, Coca A, Wei C, Rosenberg AF, Feng C, Treanor JJ, Lee FE, Sanz I.
Abstract
ABSTRACT:
INTRODUCTION:
As a group Rheumatoid arthritis (RA) patients exhibit increased risk of infection, and those treated with anti-TNF therapy are at further risk. This increased susceptibility may result from a compromised humoral immune response. Therefore, we asked if short-term effector (d5-d10) and memory (1 month or later) B cell responses to antigen were compromised in RA patients treated with anti-TNF therapy.
METHODS:
Peripheral blood samples were obtained from RA patients, including a subset treated with anti-TNF, and from healthy controls to examine influenza-specific responses following seasonal influenza vaccination. Serum antibody was measured by hemagglutination inhibition assay. The frequency of influenza vaccine-specific antibody secreting cells and memory B cells was measured by EliSpot. Plasmablasts (CD19+IgD-CD27hiCD38hi) induction was measured by flow cytometry.
RESULTS:
Compared with healthy controls, RA patients treated with anti-TNF exhibited significantly decreased influenza-specific serum antibody and memory B cell responses throughout multiple years of the study. The short-term influenza-specific effector B cell response was also significantly decreased in RA patients treated with anti-TNF as compared with healthy controls, and correlated with decreased influenza-specific memory B cells and serum antibody present at one month following vaccination.
CONCLUSION:
RA patients treated with anti-TNF exhibit a compromised immune response to influenza vaccine, consisting of impaired effector and consequently memory B cell and antibody responses. The results suggest that the increased incidence and severity of infection observed in this patient population could be a consequence of diminished antigen-responsiveness. This patient population would likely benefit from repeat vaccination and from vaccines with enhanced immunogenicity.
PMID:
22177419
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22177419
Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-TNF.
Kobie JJ, Zheng B, Bryk P, Barnes M, Ritchlin CT, Tabechian DA, Anandarajah AP, Looney RJ, Thiele RG, Anolik JH, Coca A, Wei C, Rosenberg AF, Feng C, Treanor JJ, Lee FE, Sanz I.
Abstract
ABSTRACT:
INTRODUCTION:
As a group Rheumatoid arthritis (RA) patients exhibit increased risk of infection, and those treated with anti-TNF therapy are at further risk. This increased susceptibility may result from a compromised humoral immune response. Therefore, we asked if short-term effector (d5-d10) and memory (1 month or later) B cell responses to antigen were compromised in RA patients treated with anti-TNF therapy.
METHODS:
Peripheral blood samples were obtained from RA patients, including a subset treated with anti-TNF, and from healthy controls to examine influenza-specific responses following seasonal influenza vaccination. Serum antibody was measured by hemagglutination inhibition assay. The frequency of influenza vaccine-specific antibody secreting cells and memory B cells was measured by EliSpot. Plasmablasts (CD19+IgD-CD27hiCD38hi) induction was measured by flow cytometry.
RESULTS:
Compared with healthy controls, RA patients treated with anti-TNF exhibited significantly decreased influenza-specific serum antibody and memory B cell responses throughout multiple years of the study. The short-term influenza-specific effector B cell response was also significantly decreased in RA patients treated with anti-TNF as compared with healthy controls, and correlated with decreased influenza-specific memory B cells and serum antibody present at one month following vaccination.
CONCLUSION:
RA patients treated with anti-TNF exhibit a compromised immune response to influenza vaccine, consisting of impaired effector and consequently memory B cell and antibody responses. The results suggest that the increased incidence and severity of infection observed in this patient population could be a consequence of diminished antigen-responsiveness. This patient population would likely benefit from repeat vaccination and from vaccines with enhanced immunogenicity.
PMID:
22177419
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22177419